Skip to main content

Table 1 Efficacy of select estrogens within CEE to reduce LDH release following exposure to β-amyloid25–35 in basal forebrain neurons. Neuronal cultures were pretreated with indicated estrogens for 4 days followed by a 24 hr exposure to 8 μg/ml β-amyloid25–35. The culture medium was replaced and cultures were allowed to incubate for an additional 24 hr followed by determination of LDH release into the medium. Data are represented as mean ± SEM (n = 7 – 24 from 3 separate experiments). ** P < 0.01 and *** P < 0.001 compared to β-amyloid25–35 alone-treated cultures.

From: Select estrogens within the complex formulation of conjugated equine estrogens (Premarin®) are protective against neurodegenerative insults: implications for a composition of estrogen therapy to promote neuronal function and prevent Alzheimer's disease

Treatment (pg/ml) LDH Release (% of β-amyloid25–35 alone group)
Control 36.11 ± 1.60***
β-amyloid25–35 alone 100.00 ± 2.26
17α-estradiol (10) 86.62 ± 2.99**
17β-estradiol (10) 84.20 ± 1.47***
Equilin (1000) 89.01 ± 1.74**
Equilenin (300) 81.49 ± 3.06***
17α-dihydroequilin (1000) 89.96 ± 3.88**
17β-dihydroequilin (40) 101.53 ± 2.00
Estrone (5000) 99.33 ± 4.43
Δ8,9-dehydroestrone (300) 85.82 ± 2.07***